10 Best Oncology Apps

Data from the phase 1/2 GO29781 study support the approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD.